News Sentiment

PCRX sentiment intelligence

Pacira BioSciences, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 44 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 25.48 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

86/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+0.4% over one week, +10.8% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

PCRX6079820 Bond Coupon Profile — Rate & Payments

Market Reaction

Balanced read

58/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 86/100 classification
One-week reaction 0.4% Price digesting
Trend fit Trend active 10.8% over four weeks
Fair value 2.2% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 31
Negative 0

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingView 12
Stock Titan 8
markets.businessinsider.com 2
simplywall.st 2
ChartMill 2
Market source 2
PR Newswire 2
Ad-hoc-news.de 1

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 8
Balance sheet 1
Analyst action 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 44
TradingView Direct company coverage

PCRX6079820 Bond Coupon Profile — Rate & Payments

This article provides a bond coupon profile for Pacira Biosciences, Inc.'s PCRX6079820 bond, detailing its 2.125% interest rate with a maturity date of May 15, 2029. It highlights the current coupon rate of 2.13% and indicates the next payment is scheduled for November 16, 2026.

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 07:11
Source
TradingView
TradingView Direct company coverage

PCRX6079820 Bond Risk Profile

This page provides an overview of the PCRX6079820 corporate bond issued by Pacira Biosciences, Inc., highlighting its 2.125% coupon rate and a maturity date of May 15, 2029. It outlines key metrics for risk assessment, including information on credit risk and the availability of

Tone
Neutral 50/100
Event
Balance sheet
Published
15 Jul 2026 05:11
Source
TradingView
TradingView Direct company coverage

PCRX6079820 Bond Profile — Key Metrics

This article provides key metrics for the Pacira Biosciences, Inc. 2.125% 15-MAY-2029 corporate bond, identified as PCRX6079820. It details the bond's issue and maturity dates, outstanding amount, face value, and coupon rate. Additionally, it offers a brief company profile for Pa

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 04:44
Source
TradingView
Ad-hoc-news.de Direct company coverage

Pacira BioSciences stock trades steady as pain-management pipeline stays in focus

Pacira BioSciences (PCRX) stock is trading steadily due to investor focus on non-opioid pain treatments and its specialist portfolio targeting hospitals and surgical centers. The company specializes in non-opioid pain control solutions for surgical procedures, emphasizing clinica

Tone
Positive 65/100
Event
Market update
Published
09 Jul 2026 15:10
Source
Ad-hoc-news.de
TradingView Direct company coverage

82P Forecast — Price Target — Prediction for 2027

This article provides forecasts and financial data for Pacira Biosciences, Inc. (82P) on the BX Swiss exchange. It includes analyst price targets, EPS and revenue estimates, past earnings performance, and key financial metrics like EBITDA and employee count. The company is set to

Tone
Positive 63/100
Event
Earnings
Published
09 Jul 2026 07:10
Source
TradingView
markets.businessinsider.com Direct company coverage

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences announced inducement grants to ten new employees on July 2, 2026, under its Amended and Restated 2014 Inducement Plan. These awards, consisting of stock options and restricted stock units for a total of 27,400 shares, were approved by the People & Compensation

Tone
Positive 61/100
Event
Market update
Published
08 Jul 2026 19:39
Source
markets.businessinsider.com
Stock Titan Direct company coverage

Pacira uses stock awards to recruit 10 new employees

Pacira BioSciences (Nasdaq:PCRX) has granted inducement equity awards to ten new employees under its 2014 Inducement Plan. These awards, consisting of stock options for 9,200 shares and restricted stock units (RSUs) for 18,200 shares, are intended to attract and retain talent, wi

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 12:10
Source
Stock Titan
Sahm Direct company coverage

Pacira BioSciences (PCRX) Wins Broader EXPAREL Reimbursement, Is The Stock Still Undervalued?

Pacira BioSciences (PCRX) has gained attention after UnitedHealthcare announced separate reimbursement for its non-opioid pain drug EXPAREL in outpatient surgical settings nationwide. Despite recent positive short-term stock performance and a fair value narrative suggesting under

Tone
Positive 64/100
Event
Market update
Published
08 Jul 2026 07:40
Source
Sahm
MassDevice Direct company coverage

Zimmer Biomet to pay up to $140M for Iovera nerve therapy tech from Pacira BioSciences

Zimmer Biomet is set to acquire Pacira BioSciences' Iovera nerve therapy device for an upfront payment of $70 million and potential future milestone payments of up to an additional $70 million. The Iovera device is an FDA-cleared, drug-free medical device that uses cryoneurolysis

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 07:40
Source
MassDevice
TradingView Direct company coverage

Enterprise value to revenue forward of Pacira Biosciences, Inc. – BX:82P

This article provides the enterprise value to forward revenue for Pacira Biosciences, Inc. (BX:82P). It is a brief financial data point from TradingView, which also lists market and company information and various tools for financial analysis. The information indicates the market

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 05:41
Source
TradingView
Stock Titan Direct company coverage

If You Invested $1,000 in Pacira Biosciences Inc (PCRX)

This article analyzes the historical performance of Pacira Biosciences Inc (PCRX) stock, detailing how a $1,000 investment would have fared over 1, 5, and 10 years, and against the S&P 500. It also provides an overview of Pacira BioSciences, including its focus on non-opioid pain

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 05:40
Source
Stock Titan
The Globe and Mail Direct company coverage

Pacira BioSciences Divests CryoTech to Zimmer Biomet

Pacira BioSciences has agreed to sell its Pacira CryoTech subsidiary, including the iovera° device, to Zimmer Biomet for up to $140 million. This transaction, expected to close in Q3 2026, will help Pacira shift focus from medical devices to a biopharmaceutical portfolio and pay

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 07:10
Source
The Globe and Mail
TradingView Direct company coverage

PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare

Pacira BioSciences (PCRX) announced that UnitedHealthcare will now provide separate reimbursement for its non-opioid pain medicine, Exparel, in outpatient settings. This decision is expected to improve patient access and support the use of non-opioid pain management after surgery

Tone
Positive 72/100
Event
Market update
Published
02 Jul 2026 13:40
Source
TradingView
GlobeNewswire Direct company coverage

Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®

Pacira BioSciences announced that UnitedHealthcare will now provide separate reimbursement for EXPAREL® (bupivacaine liposome injectable suspension) in outpatient settings, including hospital outpatient departments and ambulatory surgery centers. This decision expands access to n

Tone
Positive 75/100
Event
Market update
Published
02 Jul 2026 05:09
Source
GlobeNewswire
markets.businessinsider.com Direct company coverage

Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL

Pacira BioSciences announced that UnitedHealthcare will now provide separate reimbursement for EXPAREL (bupivacaine liposome injectable suspension) in outpatient settings, expanding access to non-opioid postsurgical pain management for approximately 40 million covered lives. This

Tone
Positive 75/100
Event
Market update
Published
01 Jul 2026 17:10
Source
markets.businessinsider.com
www.marketscreener.com Direct company coverage

Pacira BioSciences' Exparel Now Separately Reimbursed by UnitedHealthcare Across Outpatient Settings

Pacira BioSciences' Exparel, a long-acting local anesthetic, will now receive separate reimbursement from UnitedHealthcare for use in outpatient settings. This development is significant as it improves access to EXPAREL for pain management, which is a non-opioid treatment. The se

Tone
Positive 74/100
Event
Market update
Published
01 Jul 2026 13:12
Source
www.marketscreener.com
TradingView Direct company coverage

Price to earnings forward of Pacira BioSciences, Inc. – NASDAQ:PCRX

The article displays the "Price to earnings forward" financial metric for Pacira BioSciences, Inc. (NASDAQ: PCRX). It is presented within a TradingView interface, indicating that the data is sourced from financial services like ICE Data Services and FactSet. The page shows that m

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 06:39
Source
TradingView
TradingView Direct company coverage

Pacira Biosciences Announces Agreement To Divest Its Iovera° Business To Zimmer Biomet

Pacira Biosciences has announced an agreement to divest its Iovera° business to Zimmer Biomet. This news was reported by Reuters and Refinitiv. The article provides a brief mention of the transaction, which is less than a minute read.

Tone
Positive 64/100
Event
Market update
Published
30 Jun 2026 13:10
Source
TradingView
GuruFocus Direct company coverage

Pacira BioSciences (PCRX) Sells iovera° Business to Zimmer Biome

Pacira BioSciences (PCRX) has announced the sale of its iovera° business to Zimmer Biomet for up to $140 million, including an upfront payment of $70 million. This strategic move aims to enhance Pacira's financial position and refocus resources on its core non-opioid pain managem

Tone
Positive 74/100
Event
Market update
Published
30 Jun 2026 13:10
Source
GuruFocus
Investing.com Direct company coverage

Pacira BioSciences stock rises on Zimmer Biomet deal

Pacira BioSciences (NASDAQ:PCRX) shares rose 3.8% in premarket trading after announcing the sale of its iovera° unit to Zimmer Biomet Holdings (NYSE:ZBH) for up to $140 million. The deal includes $70 million upfront and up to $70 million in future milestone payments. Pacira inten

Tone
Neutral 50/100
Event
Deals and strategy
Published
30 Jun 2026 12:10
Source
Investing.com
Stock Titan Direct company coverage

Pacira offloads iovera° for up to $140M, keeps spasticity program

Pacira BioSciences announced the divestiture of its iovera° cryoneurolysis pain-treatment business to Zimmer Biomet for up to $140 million, including an upfront payment of $70 million. The companies will also collaborate on a spasticity program, with potential additional compensa

Tone
Positive 67/100
Event
Market update
Published
30 Jun 2026 11:10
Source
Stock Titan
TradingView Direct company coverage

Pacira BioSciences to Sell Iovera Cryoanalgesia Business to Zimmer for Up to $140 Million

Pacira BioSciences is divesting its iovera° cryoanalgesia business to Zimmer for a total consideration of up to $140 million. The deal includes an upfront payment of $70 million and up to $70 million in contingent payments tied to revenue milestones. This strategic move allows Pa

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 11:10
Source
TradingView
TradingView Direct company coverage

Price to book forward of Pacira BioSciences, Inc. – NASDAQ:PCRX

This page provides financial information for Pacira BioSciences, Inc. (NASDAQ: PCRX), specifically focusing on its "Price to book forward" metric. The content highlights various financial tools and data provided by TradingView, FactSet, and ICE Data Services.

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 09:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Pacira Biosciences, Inc. – FWB:82P

This article provides the enterprise value to EBIT forward for Pacira Biosciences, Inc. (FWB:82P) on the Frankfurt Stock Exchange. It indicates that the market was closed with no trades at the time of the report. The content also briefly outlines the navigation sections available

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 05:40
Source
TradingView